AIM ImmunoTech Inc. (), formerly known as Hemispherx Biopharma Inc., is a

biopharmaceutical A biopharmaceutical, also known as a biological medical product, or biologic, is any pharmaceutical drug product manufactured in, extracted from, or semisynthesized from biological sources. Different from totally synthesized pharmaceuticals, t ...

company based in

Ocala Ocala ( ) is a city in and the county seat of Marion County within the northern region of Florida, United States. As of the 2020 United States Census, the city's population was 63,591, making it the 54th most populated city in Florida. Home to ...

Florida Florida is a state located in the Southeastern region of the United States. Florida is bordered to the west by the Gulf of Mexico, to the northwest by Alabama, to the north by Georgia, to the east by the Bahamas and Atlantic Ocean, and to ...

. focused on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Founded in 1990, the company has 23 employees. The company has created an

immunomodulator Immunotherapy or biological therapy is the treatment of disease by activating or suppressing the immune system. Immunotherapies designed to elicit or amplify an immune response are classified as ''activation immunotherapies,'' while immunotherap ...

y double stranded RNA

drug A drug is any chemical substance that causes a change in an organism's physiology or psychology when consumed. Drugs are typically distinguished from food and substances that provide nutritional support. Consumption of drugs can be via insuffla ...

called

Ampligen Rintatolimod, sold under the tradename Ampligen, is a medication intended for treatment of chronic fatigue syndrome (CFS). There is some evidence it may improve some CFS symptoms. It is an immunomodulatory double-stranded RNA drug similar to the ...

. The company is developing Ampligen to use as a treatment for multiple cancer tumor types, COVID-19 and

chronic fatigue syndrome Chronic fatigue syndrome (CFS), also called myalgic encephalomyelitis (ME) or ME/CFS, is a complex, debilitating, long-term medical condition. The causes and mechanisms of the disease are not fully understood. Distinguishing core symptoms are ...

History

On April 3, 2001, Hemispherx Biopharma, Inc. adjusted and restated its 1999 financial statements to reflect charges relating to an extension of the exercise period to certain warrants as of February 1999. On April 3, 2006, Hemispherx Biopharma, Inc. restated financial results for 2003 and 2004 due to accounting mistakes related to debentures and warrants issued between March 2003 and August 2005. In June, 2018, Hemispherx announced that Ampligen had shown effectiveness in activating the

TLR3 Toll-like receptor 3 (TLR3) also known as CD283 (cluster of differentiation 283) is a protein that in humans is encoded by the ''TLR3'' gene. TLR3 is a member of the toll-like receptor family of pattern recognition receptors of the innate immune s ...

without triggering T-cell regulatory activities, offering a potentially effective way to treat tumors. As of June 2019, Hemispherx is operating 5 studies examining the viability of Ampligen for combating

Ovarian cancer Ovarian cancer is a cancerous tumor of an ovary. It may originate from the ovary itself or more commonly from communicating nearby structures such as fallopian tubes or the inner lining of the abdomen. The ovary is made up of three different c ...

, to which end it has also raised tens of millions of dollars in shareholder capital. On September 3, 2019, Hemispherx Biopharma was renamed to AIM Immunotech. On March 12, 2020, Hemispherx Biopharma announced that they were testing a possible treatment for the novel coronavirus, the virus believed to cause the symptoms of COVID-19.

References

{{reflist

External links

Official website
Biopharmaceutical companies Companies based in Philadelphia Pharmaceutical companies established in 1990 Companies listed on NYSE American